COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company is honored and thrilled to announce that Dr. Ritchard L. Fishman has accepted its request to become a member of its recently formed Scientific Advisory Board.
Dr. Fishman established his practice in 1961, and since then has been seeing patients of all ages for Diabetes, Hypertension, Weight Loss, Arthritis, Pain Management and many other medical problems. Dr. Fishman is widely recognized as a leader in the research in these fields. Since 1998, Dr. Fishman has been involved in clinical trials for medications, treatments, devices and vaccines for major pharmaceutical companies seeking FDA approval. Dr. Fishman is also a Chairman of the New Life Diabetes Center’s Medical Review Board and is responsible for reviewing all medical operations supervised by this Center. Dr. Fishman graduated Ohio State University in 1953 where he earned a Bachelor of Science degree with a Major in Biology. He also received his Medical Doctor degree from Ohio State University in 1957. Dr. Fishman has professional affiliations with the Downey Community Hospital, Whittier Presbyterian Hospital, and Whittier Hospital. Also, he has been a guest lecturer with the Western University School of Osteopathic Medicine and Senior Medical advisor for New Life Diabetic Centers in California and Nevada.
Dr. Robert Melamede, Cannabis Science Inc.’s President and CEO said, “We are pleased to announce the appointment of Dr. Ritchard Fishman as the second member of our Scientific Advisory Board. Dr. Fishman has worldwide recognition as a leading medical doctor in treatment of Pain Management, Diabetes and Weight Loss. Having Dr. Fishman on our Scientific Advisory Board alongside Dr. Mitch Earleywine will bring us even closer to our goal of providing FDA approved cannabis medications. Dr. Fishman’s acceptance of this position is very exciting and we are thrilled to have him as part of our growing medical team.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” “intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO, 1-888-889-0888
Brokers and Analysts:
Wall Street International
John Campo, 1-410-236-8200
Catalyst Xchange Corp.
Donald Shaxon, 1-416-368-3116